A phase II trial of vincristine in advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study
| Autor: | Mark D. Adelson, Gary L. Eddy, G. O. Broun, John A. Blessing |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Vincristine Vinca medicine.medical_treatment Gynecologic oncology Gastroenterology Bolus (medicine) Internal medicine Carcinoma medicine Humans Aged Chemotherapy biology Epithelioma business.industry Remission Induction Middle Aged medicine.disease biology.organism_classification Surgery Endometrial Neoplasms Oncology Female business Progressive disease medicine.drug |
| Zdroj: | American journal of clinical oncology. 16(1) |
| ISSN: | 0277-3732 |
| Popis: | Thirty-three evaluable patients who had not received prior chemotherapy were entered on a study of vincristine therapy for advanced or recurrent endometrial carcinoma. Vincristine 1.4 mg/m2 was given weekly as an i.v. bolus for 4 weeks and then every other week. There was one complete response (CR) lasting 5 months. Five patients had partial responses (PR) lasting 3–18 months. The CR + PR rate was 18% (95% confidence interval for CR + PR was 7–36%). Thirteen patients (38%) had stable disease from 2–28 months, and 14 had progressive disease. The major toxicity was neurological, with 11 patients having grade 2 or 3 peripheral neuropathy. Vincristine at this dose and schedule has modest activity, but troublesome toxicity in advanced or recurrent endometrial carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|